FREMONT, Calif., Feb. 24, 2025 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the release of the ...

Explore how proteomics in biomarker discovery accelerates diagnostic assay development and improves clinical validation.

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancerLicensing deal reflects ...

The SPEAR UltraDetect ™ pTau 217 biomarker assay kit is a specialized tool for researching Alzheimer’s disease (AD) using plasma samples. The assay requires the SPEAR UltraDet ...

Please provide your email address to receive an email when new articles are posted on . Octave Bioscience Inc. has received a $10M grant from the Michael J. Fox Foundation for Parkinson’s Research to ...

Background: The Prognostic Lung Fibrosis Consortium (PROLIFIC) was formed to develop well-qualified assays suitable for use as prognostic biomarkers within the context of clinical trials for Idiopathic ...

The CHAI platform extracted quantitative histomorphologic features from whole-slide images of hematoxylin and eosin–stained diagnostic biopsies. In a multi-institutional development cohort, features ...

Dr. Stephen will cover the process of developing and manufacturing reliable Luminex biomarker assays, as well as using those assays to test samples. She will examine the development of Ampersand ...